Santa Clara-based Affymetrix Inc. and Vanderbilt-Ingram Cancer Center announced that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, researchers at Vanderbilt-Ingram and Vanderbilt University Medical Center will use Affymetrix GeneChip microarray technology to develop new applications for translational research projects, focusing on disease areas such as cancer and HIV/AIDS.

“Cancer is a genetic disease. The technological capabilities that Affymetrix provides in gene expression and genotyping provides an important set of tools to examine the molecular and genetic basis of cancer,” said Shawn Levy, Ph.D., assistant professor of biomedical informatics and director of the Vanderbilt Microarray Shared Resource. “This partnership provides a mechanism to bring these technologies to the forefront of translational research in helping Vanderbilt understand not only the molecular basis for the disease but also the genetic disparities in various cancers and responses to therapy.”

Posted on January 29, 2007 11:27 AM